Key points are not available for this paper at this time.
The COVID-19 pandemic demonstrated both the transformative capacity of vaccine innovation and the persistent inequities that accompany emergency access, underscoring the critical need for stronger collaboration between global health governance and the vaccine industry. Influenza pandemics remain inevitable threats. The continued emergence of avian influenza strains such as H5N1 reinforces the necessity of robust preparedness. This perspective examines the underutilization of private sector vaccine manufacturers in current pandemic influenza frameworks and identifies three central areas where industry participation is indispensable: predictable vaccine demand through robust seasonal influenza programs, economic incentives that de-risk investments in research and development, and diversification of vaccine platforms to expand response capacity. In addition, regionalizing manufacturing, advancing collaborative regulatory models, and negotiating export waivers are presented as potential mechanisms to strengthen equity and supply security. The review highlights demand-based tiered pricing and Advance Purchase Agreements as practical tools to align commercial incentives with public health priorities. Furthermore, it makes the case for embedding private sector representation and knowledge into top-level decision-making and preparedness planning, ensuring investment in innovation is aligned with global health objectives. Ultimately, true pandemic influenza readiness depends on building a sustained seasonal influenza market, embedding private sector engagement into governance structures, and fostering mutual trust to ensure timely access and equitable protection for populations worldwide.
Marsden et al. (Wed,) studied this question.